These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
280 related articles for article (PubMed ID: 27161214)
1. Understanding the Different Effects of Inhaler Design on the Aerosol Performance of Drug-Only and Carrier-Based DPI Formulations. Part 1: Grid Structure. Leung CMS; Tong Z; Zhou QT; Chan JGY; Tang P; Sun S; Yang R; Chan HK AAPS J; 2016 Sep; 18(5):1159-1167. PubMed ID: 27161214 [TBL] [Abstract][Full Text] [Related]
2. The effects of loaded carrier mass and formulation mass on aerosolization efficiency in dry powder inhaler devices. Ooi J; Gill C; Young PM; Traini D Curr Drug Deliv; 2015; 12(1):40-6. PubMed ID: 25146438 [TBL] [Abstract][Full Text] [Related]
3. Effect of device design on the aerosolization of a carrier-based dry powder inhaler--a case study on Aerolizer(®) Foradile (®). Zhou QT; Tong Z; Tang P; Citterio M; Yang R; Chan HK AAPS J; 2013 Apr; 15(2):511-22. PubMed ID: 23371759 [TBL] [Abstract][Full Text] [Related]
5. Effect of Roughness on the Dispersion of Dry Powders for Inhalation: a Dynamic Visualization Perspective. Kou X; Heng PWS; Chan LW; Wereley ST; Carvajal MT AAPS PharmSciTech; 2019 Jul; 20(7):271. PubMed ID: 31363868 [TBL] [Abstract][Full Text] [Related]
6. Evaluation of Granulated Lactose as a Carrier for Dry Powder Inhaler Formulations 2: Effect of Drugs and Drug Loading. Du P; Du J; Smyth HDC J Pharm Sci; 2017 Jan; 106(1):366-376. PubMed ID: 27939234 [TBL] [Abstract][Full Text] [Related]
7. Aerosolization characteristics of dry powder inhaler formulations for the excipient enhanced growth (EEG) application: effect of spray drying process conditions on aerosol performance. Son YJ; Worth Longest P; Hindle M Int J Pharm; 2013 Feb; 443(1-2):137-45. PubMed ID: 23313343 [TBL] [Abstract][Full Text] [Related]
8. Air classifier technology (ACT) in dry powder inhalation Part 4. Performance of air classifier technology in the Novolizer multi-dose dry powder inhaler. de Boer AH; Hagedoorn P; Gjaltema D; Goede J; Frijlink HW Int J Pharm; 2006 Mar; 310(1-2):81-9. PubMed ID: 16442246 [TBL] [Abstract][Full Text] [Related]
9. Preparation and Evaluation of Surface Modified Lactose Particles for Improved Performance of Fluticasone Propionate Dry Powder Inhaler. Singh DJ; Jain RR; Soni PS; Abdul S; Darshana H; Gaikwad RV; Menon MD J Aerosol Med Pulm Drug Deliv; 2015 Aug; 28(4):254-67. PubMed ID: 25517187 [TBL] [Abstract][Full Text] [Related]
10. Formulating powder-device combinations for salmeterol xinafoate dry powder inhalers. Hassoun M; Ho S; Muddle J; Buttini F; Parry M; Hammond M; Forbes B Int J Pharm; 2015 Jul; 490(1-2):360-7. PubMed ID: 25987210 [TBL] [Abstract][Full Text] [Related]
11. Effect of carrier particle shape on dry powder inhaler performance. Kaialy W; Alhalaweh A; Velaga SP; Nokhodchi A Int J Pharm; 2011 Dec; 421(1):12-23. PubMed ID: 21945739 [TBL] [Abstract][Full Text] [Related]
12. Effect of Dosing Cup Size on the Aerosol Performance of High-Dose Carrier-Based Formulations in a Novel Dry Powder Inhaler. Yeung S; Traini D; Tweedie A; Lewis D; Church T; Young PM J Pharm Sci; 2019 Feb; 108(2):949-959. PubMed ID: 30312722 [TBL] [Abstract][Full Text] [Related]
13. Humidity-induced changes of the aerodynamic properties of dry powder aerosol formulations containing different carriers. Zeng XM; MacRitchie HB; Marriott C; Martin GP Int J Pharm; 2007 Mar; 333(1-2):45-55. PubMed ID: 17064863 [TBL] [Abstract][Full Text] [Related]
14. Evaluation of granulated lactose as a carrier for DPI formulations 1: effect of granule size. Du P; Du J; Smyth HD AAPS PharmSciTech; 2014 Dec; 15(6):1417-28. PubMed ID: 24962007 [TBL] [Abstract][Full Text] [Related]
15. The contribution of different formulation components on the aerosol charge in carrier-based dry powder inhaler systems. Hoe S; Traini D; Chan HK; Young PM Pharm Res; 2010 Jul; 27(7):1325-36. PubMed ID: 20354768 [TBL] [Abstract][Full Text] [Related]
16. Improved aerosolization performance of salbutamol sulfate formulated with lactose crystallized from binary mixtures of ethanol-acetone. Kaialy W; Ticehurst MD; Murphy J; Nokhodchi A J Pharm Sci; 2011 Jul; 100(7):2665-84. PubMed ID: 21268026 [TBL] [Abstract][Full Text] [Related]
17. Investigations on the Mechanism of Magnesium Stearate to Modify Aerosol Performance in Dry Powder Inhaled Formulations. Jetzer MW; Schneider M; Morrical BD; Imanidis G J Pharm Sci; 2018 Apr; 107(4):984-998. PubMed ID: 29247741 [TBL] [Abstract][Full Text] [Related]
18. Effects of the mouthpiece and chamber of Turbuhaler® on the aerosolization of API-only powder formulations. Zhu Q; Gou D; Chan HK; Kourmatzis A; Yang R Int J Pharm; 2023 Apr; 637():122871. PubMed ID: 36948474 [TBL] [Abstract][Full Text] [Related]
19. Effect of design on the performance of a dry powder inhaler using computational fluid dynamics. Part 1: Grid structure and mouthpiece length. Coates MS; Fletcher DF; Chan HK; Raper JA J Pharm Sci; 2004 Nov; 93(11):2863-76. PubMed ID: 15389665 [TBL] [Abstract][Full Text] [Related]
20. Is the cellular uptake of respiratory aerosols delivered from different devices equivalent? Ong HX; Traini D; Loo CY; Sarkissian L; Lauretani G; Scalia S; Young PM Eur J Pharm Biopharm; 2015 Jun; 93():320-7. PubMed ID: 25930239 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]